Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, discusses disruptive technologies that may change the cell therapy landscape. Specifically discussed is the formation of an off-the-shelf T-cell product able to treat solid tumors with the same potency and efficacy seen with current cellular therapies. This interview took place during the 2020 Meeting on the Mesa congress.